1. Home
  2. ASMB vs EDAP Comparison

ASMB vs EDAP Comparison

Compare ASMB & EDAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ASMB
  • EDAP
  • Stock Information
  • Founded
  • ASMB 2005
  • EDAP 1979
  • Country
  • ASMB United States
  • EDAP France
  • Employees
  • ASMB N/A
  • EDAP N/A
  • Industry
  • ASMB Biotechnology: Pharmaceutical Preparations
  • EDAP Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • Sector
  • ASMB Health Care
  • EDAP Health Care
  • Exchange
  • ASMB Nasdaq
  • EDAP Nasdaq
  • Market Cap
  • ASMB 84.5M
  • EDAP 81.6M
  • IPO Year
  • ASMB 2010
  • EDAP 1997
  • Fundamental
  • Price
  • ASMB $12.48
  • EDAP $2.78
  • Analyst Decision
  • ASMB Buy
  • EDAP Strong Buy
  • Analyst Count
  • ASMB 2
  • EDAP 1
  • Target Price
  • ASMB $35.00
  • EDAP $19.00
  • AVG Volume (30 Days)
  • ASMB 23.1K
  • EDAP 39.9K
  • Earning Date
  • ASMB 03-27-2025
  • EDAP 03-26-2025
  • Dividend Yield
  • ASMB N/A
  • EDAP N/A
  • EPS Growth
  • ASMB N/A
  • EDAP N/A
  • EPS
  • ASMB N/A
  • EDAP N/A
  • Revenue
  • ASMB $28,326,000.00
  • EDAP $70,722,730.00
  • Revenue This Year
  • ASMB $282.16
  • EDAP $6.96
  • Revenue Next Year
  • ASMB N/A
  • EDAP $15.53
  • P/E Ratio
  • ASMB N/A
  • EDAP N/A
  • Revenue Growth
  • ASMB N/A
  • EDAP 12.17
  • 52 Week Low
  • ASMB $11.05
  • EDAP $2.00
  • 52 Week High
  • ASMB $19.93
  • EDAP $8.50
  • Technical
  • Relative Strength Index (RSI)
  • ASMB 37.42
  • EDAP 67.21
  • Support Level
  • ASMB $12.10
  • EDAP $2.46
  • Resistance Level
  • ASMB $13.25
  • EDAP $2.90
  • Average True Range (ATR)
  • ASMB 0.58
  • EDAP 0.16
  • MACD
  • ASMB -0.10
  • EDAP 0.04
  • Stochastic Oscillator
  • ASMB 14.79
  • EDAP 81.82

About ASMB Assembly Biosciences Inc.

Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two innovative platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.

About EDAP EDAP TMS S.A.

Edap TMS SA is a holding company operating in three divisions namely, HIFU (High-Intensity Focused Ultrasound), ESWL (Extracorporeal ShockWave Lithotripsy), and Distribution. The HIFU division develops, manufactures, and markets devices for the invasive destruction of certain types of tumors using HIFU technology. It markets three HIFU devices: the Ablatherm, Ablatherm Fusion, and the Focal One. The ESWL division is engaged in the manufacturing, marketing, and servicing of its installed base of Sonolith range of lithotripters. The Distribution division markets products that are complementary to its global activity such as lasers, micro-ultrasound systems, and other medical products from third parties. Its geographical segments are Asia, France, United States, and Others.

Share on Social Networks: